SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Vitaspring Biomedical posts zero revenue, wider quarterly loss

The company reported third-quarter 2026 revenue of $0 and a net loss of $155,817, versus a loss of $110,845 a year earlier. Diluted EPS was $(0.00).

VSBC

VITASPRING BIOMEDICAL CO. LTD. reported results for the third quarter ended July 31, 2026, with no revenue and a net loss of $155817 or diluted EPS of $(0.00), compared with a net loss of $110845 and EPS of $(0.00) in the year—ago quarter.Financial HighlightsBusiness HighlightsOriginal SEC Filing…

Related stories